Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.45 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.45 |
| ▸ | PNP | P00491 | 1/20 | 0.43 |
| ▸ | TK1 | P04183 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TK2 | O00142 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6062710 | 1.00 | ADRB1 (0.45) | ADRB1DNMT1PNPTK1LMNA | |
| SCHEMBL12123502 | 0.81 | ADRB1 (0.47) | ADRB1DNMT1PNPTK1LMNA | |
| SCHEMBL14570606 | 0.81 | ADRB1 (0.47) | ADRB1DNMT1PNPTK1LMNA | |
| SCHEMBL19033338 | 0.81 | PNP (0.54) | ADRB1DNMT1PNPTK1LMNA | |
| SCHEMBL889695 | 0.81 | ADRB1 (0.47) | ADRB1DNMT1PNPTK1LMNA | |
| SCHEMBL23786492 | 0.81 | ADRB1 (0.47) | ADRB1DNMT1PNPTK1LMNA | |
| SCHEMBL3868526 | 0.81 | PNP (0.54) | ADRB1DNMT1PNPTK1LMNA | |
| SCHEMBL6061911 | 0.80 | PNP (0.43) | ADRB1DNMT1PNPTK1LMNA | |
| SCHEMBL6061917 | 0.80 | PNP (0.43) | ADRB1DNMT1PNPTK1LMNA | |
| SCHEMBL7632796 | 0.79 | PNP (0.53) | ADRB1DNMT1PNPTK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0710667-B1 | Modified oligonucleotides, their preparation and their use | ROCHE DIAGNOSTICS GMBH (DE) | 2011-12-14 | — | — | EP | disclosed |
| US-6987177-B2 | Modified oligonucleotides, their preparation and their use | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2006-01-17 | — | — | US | disclosed |
| US-20030096981-A1 | Modified oligonucleotides, their preparation and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-05-22 | — | — | US | disclosed |
| US-6479651-B1 | Modified oligonucleotides, their preparation and their use | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-11-12 | — | — | US | disclosed |
| US-6150510-A | NUCLEOTIDES/NUCLEOSIDES WITH SUBSTITUTED 7-DEAZAPURINE BASE FORM MORE STABLE HYBRIDIZATION COMPLEXES; GENETIC PROBES; ANTISENSE AGENTS; GENE EXPRESSION INHIBITION; DIAGNOSTIC AGENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096981-A1 | Modified oligonucleotides, their preparation and their use | NSUN2, TYMP, ADAR | ADRB1 4244/4885DNMT1 134/4885PNP 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.